Skip to content

Contact


MMRGlobal, Inc.
4401 Wilshire Blvd.
2nd Floor
Los Angeles, CA 90010
1-888-808-4667
Email: info@mmrmail.com


Transfer Agent: Computershare

Mailing Addresses:

Shareholder correspondence should be mailed to:
Computershare
P.O. Box 43006
Providence, RI 02940-3006


Overnight correspondence should be mailed to:
Computershare
250 Royall Street
Canton, MA 02021


Shareholder Website:
www.computershare.com/investor

Shareholder Online Inquiries:
https://www-us.computershare.com/investor/Contact

Press Releases


Printer Friendly Version View printer-friendly version
<< Back
MMRGlobal Receives Significant Intellectual Property Milestone Payment

LOS ANGELES, CA -- (Marketwired) -- 09/17/14 -- MMRGlobal, Inc. (OTCQB: MMRF) ("MMR" or the "Company") today announced that it has received another significant milestone payment pursuant to an existing Non-Exclusive License Agreement (the "Agreement") pertaining to the Company's biotech assets. Additional information regarding this milestone payment will be contained in the Company's quarterly report on Form 10-Q for the quarter ending September 30, 2014. The non-exclusive Agreement licenses the use of the Company's clinical and scientific data relating to targeted immunotherapies for cancer and other disease treatments to stimulate a patient's immune response and certain other confidential information.

MMRGlobal's licensed assets are part of the Company's worldwide intellectual property rights to numerous biotech assets including international patents, vaccine and patient samples and anti-CD20 monoclonal antibodies.

Although MMR's primary focus is as a provider and licensor of health IT products and services, it has a growing list of patents and other intellectual property related to cancer-fighting anti-CD20 monoclonal antibodies under the title, "Antibodies and Methods For Making and Using Them," issued in the U.S., Mexico, Australia and South Korea with patents pending in the U.S., Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea. The Company also holds additional patents pertaining to its B-cell idiotype vaccine worldwide.

Additionally, through its wholly owned subsidiary, MyMedicalRecords, Inc., the Company has a health IT patent portfolio consisting of 13 issued U.S. patents, 17 pending U.S. applications, and numerous issued patents and pending applications in other countries or regional authorities of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel and Europe. The Company's primary business is selling and licensing Personal Health Records products and services and other patented health information technologies to physicians, hospitals and other healthcare providers and also retailers, employers and professional organizations.

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of MMR's products and services at www.mmrtheater.com. Follow us on Facebook.com/MMRGlobal and Twitter.com/mmrglobal.

Forward-Looking Statements
All statements in this release that are not strictly historical facts are "forward-looking statements." Such forward-looking statements are based on MMR's current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR's actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," "continue," and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR's ability to develop, license and monetize its patents in the portfolio for both MMR's health IT and biotechnology IP assets; the timing of milestone payments in connection with licensing its IP; reliance upon the successful operations of its business partners in selling MMR's products and services; MMR's ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of electronic records in clinical trials. These factors and others are described in more detail in MMR's public filings with the Securities and Exchange Commission, including the risks discussed in the "Risk Factors" section in MMR's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR's website (www.mmrglobal.com) under the heading "Investor Relations." MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Michael Selsman
Public Communications Co.
(310) 922-7033
ms@publiccommunications.biz

Source: MMRGlobal, Inc.